Rising healthcare costs and changing coverage increase financial burdens for individuals with hereditary conditions like ...
During the 2025 American Society of Hematology annual meeting, held earlier this month in Orlando, Florida, CURE sat down ...
Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast ...
High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...
Preoperative breast MRI did not improve LRR, DRFR, or OS outcomes in early-stage breast cancer patients. The trial involved ...
Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior ...
The addition of the immune checkpoint inhibitor Tecentriq (atezolizumab) to neoadjuvant chemotherapy and as a single agent ...
Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or ...
In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.
A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL ...
Standard-of-care treatment with Janus kinase inhibitor monotherapy improves splenomegaly and symptom burden but provides ...
“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback